Erasca, Inc. (ERAS) company profile
Close on Nov 17, 2026Market cap $4.86BP/E –Yield 0.00%
About Erasca
Pharmaceutical Preparations, SIC 2834
Erasca is a clinical-stage precision oncology company that discovers, develops, and commercializes targeted therapies for patients with cancers driven by the RAS/MAPK signaling pathway. The company’s modality-agnostic pipeline includes clinical-stage drug candidates such as ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, as well as discovery-stage assets like ERAS-12, an anti-EGFR biparatopic antibody. Its therapies address multiple signaling nodes, direct RAS mechanisms, and pathway escape routes to overcome treatment resistance. Erasca designs its product candidates for individuals diagnosed with solid tumors and other malignancies associated with RAS and MAPK pathway alterations.
Erasca conducts research and clinical development internationally, with clinical trials taking place in the United States and China. The organization licenses and acquires therapeutic candidates from multiple geographic territories through partnerships with third-party pharmaceutical entities. It also maintains Erasca Ventures, an investment subsidiary targeting early-stage biotechnology firms, and supports the Erasca Foundation, a California public benefit corporation. The provided text does not state the company's headquarters location or employee headcount.
Summary of the business section of Erasca's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Erasca, Inc.
- Headquarters
- San Diego, CA
- Address
- 3115 Merryfield Row, Third Floor 92121
- Phone
- (858) 465-6511
- Website
- erasca.com
- Employees
- 103, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- ERAS
- Exchange
- Nasdaq
- IPO date
- Jul 16, 2021
- Shares outstanding
- 350M, Aug 4, 2026
- Public float
- $316.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1761918
- CUSIP
- 29479A108
- ISIN
- US29479A1088
- FIGI
- BBG00MTSR883
- Share class FIGI
- BBG00MTSR892
- EIN
- 83-1217027
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan E. Lim | Chairman & CEO, Director | 32,355,576 |
| Charles S. Fuchs | President, R&D | – |
| Ebun Garner | Chief Legal Officer | 105,076 |
| Shannon Morris | Chief Medical Officer | 20,000 |
| David M. Chacko | CFO and CBO | 279,980 |
| Pratik S. Multani | Director | 172,866 |
| Julie Hambleton | Director | 6,000 |
| Valerie Denise Harding Start | Director | 22,000 |
| Alexander W. Casdin | Director | 667,724 |
| James Arthur Bristol | Director | 207,500 |
| Jean I. Liu | Director | – |
| Michael David Varney | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Jonathan E. Lim, M.D. Chairman, Chief Executive Officer, and Co-Founder | $670.40K | $3.14M | $482.69K | $10.50K | $4.30M | +10% |
| David M. Chacko, M.D. Chief Financial Officer and Chief Business Officer | $516.70K | $1.00M | $248.02K | $10.50K | $1.78M | -6% |
| Shannon R. Morris, M.D., Ph.D. Chief Medical Officer | $515.00K | $978.20K | $247.20K | $10.50K | $1.75M | +10% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 16, 2021
- Offer price
- $16.00
- Securities offered
- 18,750,000
- Gross proceeds
- $300.00M
- Exchange
- Nasdaq
- First trading day
- Jul 16, 2021
- First-day close
- $17.43+8.9%
- Lock-up ends (est.)
- Jan 12, 2022
“The initial public offering price is $16.00 per share of common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 103 full-time employees (FTEs), 34 of whom have doctorate degrees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 16, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 13, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?